Leqvio (Inclisiran) FAERS Safety Signals: What the Post-Market Data Shows

How Inclisiran Works and Why FAERS Monitoring Matters

Inclisiran is a synthetic double-stranded siRNA conjugated to triantennary N-acetylgalactosamine (GalNAc), which directs the molecule to hepatocytes. Once inside the cell, it binds to the RNA-induced silencing complex (RISC) and degrades PCSK9 messenger RNA, preventing PCSK9 protein synthesis. This reduces the recycling of LDL receptors for degradation, leaving more receptors on the hepatocyte surface to clear circulating LDL cholesterol 1.

The mechanism differs fundamentally from monoclonal antibody PCSK9 inhibitors like evolocumab and alirocumab. Those drugs bind circulating PCSK9 protein extracellularly. Inclisiran acts intracellularly at the mRNA level. This distinction matters for safety surveillance because siRNA therapeutics carry a different theoretical risk profile, including off-target gene silencing and immune activation through toll-like receptor (TLR) pathways 2.

The FDA Adverse Event Reporting System (FAERS) collects voluntary reports from healthcare professionals, patients, and manufacturers. It is the primary U.S. post-market surveillance tool for identifying safety signals that may not have emerged during clinical trials. For a drug like inclisiran with a novel mechanism and a relatively compressed pre-approval exposure base (approximately 3,600 patients across the ORION program), FAERS monitoring is particularly informative. Signals in FAERS do not confirm causation. They identify disproportionality that warrants investigation 3.

Pre-Approval Safety Profile: What ORION-10 and ORION-11 Established

The two key Phase III trials, ORION-10 (U.S.-based, atherosclerotic cardiovascular disease) and ORION-11 (ex-U.S., ASCVD or ASCVD risk equivalent), enrolled a combined 3,178 patients randomized to inclisiran 284 mg or placebo. Both were double-blind, placebo-controlled, and ran for 540 days 1.

In ORION-10, inclisiran reduced LDL-C by 52.3% at day 510 (time-averaged reduction: 53.8%). ORION-11 showed a 49.9% reduction at day 510 (time-averaged: 49.2%). These reductions were consistent across subgroups, including patients on maximally tolerated statin therapy 1.

Safety findings from pooled ORION-10 and ORION-11 data:

• Injection-site reactions occurred in 8.2% of inclisiran patients versus 1.8% on placebo. Most were mild (grade 1) and self-limiting, resolving within one to two days. No patient discontinued due to injection-site reactions.
• Serious adverse events were balanced between groups (22.4% inclisiran vs. 22.5% placebo).
• Hepatic safety showed no significant between-group differences in ALT or AST elevations >3× the upper limit of normal.
• Deaths occurred at similar rates: 2.7% (inclisiran) versus 2.7% (placebo).
• Bronchitis appeared slightly more often in the inclisiran group (4.3% vs. 2.7%), though this was not statistically significant after multiplicity adjustment.

Dr. Kausik Ray, lead author of the ORION-11 trial, stated: "The twice-yearly dosing regimen maintained consistent LDL-C lowering over 18 months with a safety profile comparable to placebo, aside from injection-site reactions" 1.

FAERS Signal Detection: Post-Market Adverse Event Patterns

Since Leqvio's U.S. launch in early 2022, FAERS data has accumulated a growing body of reports. Signal detection in FAERS relies on disproportionality analysis, typically using the Reporting Odds Ratio (ROR) or the Empirical Bayesian Geometric Mean (EBGM). A signal is flagged when a drug-event pair appears more frequently than expected compared to all other drugs in the database 3.

Key adverse event categories reported for inclisiran in FAERS through available public quarterly data extracts include:

Injection-site reactions remain the most frequently reported event, consistent with the clinical trial signal. Reports describe erythema, induration, and pain at the injection site. A smaller subset describes persistent nodules lasting weeks, which was less prominent in the trial data. This extended duration pattern represents a potential signal refinement worth monitoring 4.

Myalgia and musculoskeletal pain have appeared with notable frequency. The clinical challenge here is confounding: most inclisiran recipients also take statins, which are independently associated with muscle complaints in up to 10-29% of patients depending on the definition used 5. Disentangling statin-related myalgia from a potential inclisiran-specific signal requires careful case-level review, including dechallenge/rechallenge data.

Hepatic enzyme elevations appear in FAERS, though the signal strength is lower than for injection-site events. Given that inclisiran's mechanism concentrates activity in hepatocytes and the GalNAc conjugate specifically targets the asialoglycoprotein receptor on liver cells, hepatic safety remains a theoretical concern under active monitoring. The FDA label recommends monitoring liver function as clinically indicated 6.

Hypersensitivity reactions including rash, urticaria, and pruritus (beyond injection sites) have been reported. siRNA molecules can activate innate immune pathways, and chemical modifications to inclisiran's backbone (2'-O-methyl and 2'-fluoro substitutions) were engineered specifically to reduce this risk 2. FAERS reports of systemic hypersensitivity remain infrequent relative to the estimated prescription volume.

Reading the FDA Label: Current Warnings and Precautions

The Leqvio prescribing information, approved December 2021, contains no boxed warning 6. The Warnings and Precautions section is brief compared to many cardiovascular drugs.

The label's adverse reactions section lists injection-site reactions as the only adverse event occurring at a rate >5% above placebo. Specific language notes that reactions were "more common with inclisiran than with placebo (8.2% vs. 1.8%)" and that "the most common injection-site reactions were injection-site reaction (5.0%), injection-site pain (1.6%), and injection-site erythema (1.3%)."

No contraindications are listed beyond hypersensitivity to inclisiran or any excipient.

The label does not include warnings for hepatotoxicity, renal impairment, or drug interactions. The absence of drug interaction warnings reflects inclisiran's metabolism through nucleases rather than cytochrome P450 enzymes, which means it does not compete with the extensive list of CYP-metabolized drugs that many cardiovascular patients take 6.

The European Medicines Agency (EMA) European Public Assessment Report (EPAR) for Leqvio, published in November 2020, provides additional granularity. The EMA's Committee for Medicinal Products for Human Use (CHMP) specifically noted the injection-site reaction profile and requested ongoing periodic safety update reports (PSURs) with focused analyses on hepatic events and immunogenicity 7.

Comparing FAERS Signals: Inclisiran vs. PCSK9 Monoclonal Antibodies

Context matters when interpreting inclisiran's FAERS profile. Evolocumab (Repatha) and alirocumab (Praluent) have been on the market since 2015, giving them a much larger post-market exposure base.

Evolocumab's FAERS profile shows injection-site reactions at a lower reporting rate than inclisiran, which aligns with clinical trial data showing approximately 3.2% injection-site reactions with evolocumab versus 1.5% placebo in the FOURIER trial (N=27,564) 8. Evolocumab's FAERS data also includes neurocognitive event reports, which prompted an FDA-requested neurocognitive substudy (EBBINGHAUS) that found no difference versus placebo 9.

For inclisiran, neurocognitive event reporting in FAERS has not reached a signal threshold as of available data. This is reassuring, though the exposure base is still smaller. ORION-10 and ORION-11 did not include formal neurocognitive assessments 1.

One area where inclisiran differs is the every-six-month dosing. A missed or delayed dose of evolocumab or alirocumab leads to a relatively rapid LDL-C rebound. Inclisiran's prolonged duration of action (because the RISC complex remains active in hepatocytes for months) means that even with delayed dosing, LDL-C suppression persists longer. This pharmacodynamic feature has safety implications: if an adverse event occurs, the drug effect cannot be rapidly reversed. No antidote exists for inclisiran. The prescribing information does not address this irreversibility directly, but it is a consideration that the 2022 American Heart Association scientific statement on PCSK9 inhibition acknowledged 10.

The ORION-4 Cardiovascular Outcomes Trial: What to Expect

ORION-10 and ORION-11 were lipid-lowering efficacy trials. They were not powered for cardiovascular outcomes. The ongoing ORION-4 trial (NCT03705234) is a randomized, double-blind outcomes study enrolling approximately 15,000 patients with pre-existing ASCVD. Its primary endpoint is time to first major adverse cardiovascular event (MACE). Results are expected in late 2026 11.

ORION-4 will also provide the largest safety dataset for inclisiran. With 15,000 patients followed for a median of approximately five years, rarer adverse events that FAERS and the Phase III trials could not reliably detect may emerge. The trial uses an independent Data Safety Monitoring Board (DSMB) with pre-specified stopping rules for safety and efficacy.

The Endocrine Society's 2023 clinical practice guideline on lipid management noted that "cardiovascular outcome data for inclisiran are pending, and prescribers should weigh the LDL-C lowering evidence against the absence of proven MACE reduction when selecting among PCSK9-targeted therapies" 12.

Practical Guidance: Monitoring and Reporting for Clinicians

Clinicians prescribing Leqvio should understand how to interpret FAERS in context and how to contribute to the surveillance system.

Before each injection, assess the prior injection site for persistent reactions. Document any nodules, induration, or erythema lasting more than seven days, as these may represent the extended-duration pattern emerging in post-market reports. Rotate injection sites (abdomen, upper arm, thigh) per the label.

Hepatic monitoring is not mandated on the label, but obtaining baseline liver function tests before initiating inclisiran and rechecking at three to six months is reasonable given the hepatocyte-targeted mechanism. The American Association of Clinical Endocrinology (AACE) 2022 algorithm recommends baseline hepatic panel for patients starting any new lipid-lowering therapy 13.

Reporting to FAERS can be done through the FDA's MedWatch portal. Clinicians should report any serious adverse event (hospitalization, disability, life-threatening event, or death), any event not listed on the current label, and any event that seems disproportionate in severity to what the label describes. Voluntary reporting is the backbone of post-market surveillance. Under-reporting remains the system's primary limitation.

Patient counseling should include the fact that inclisiran's effect lasts months after each injection. If a patient develops a concerning adverse event, the drug cannot be "stopped" in the way an oral medication can. Supportive management is the standard approach while the siRNA effect wanes over subsequent months.

Patients with a prior severe injection-site reaction to any subcutaneous biologic should be monitored for 30 minutes after the first Leqvio injection, though this is not a label requirement. Clinicians should use clinical judgment for subsequent doses based on the patient's individual response history.

The current FDA label lists no dose adjustment for renal impairment (eGFR ≥15 mL/min/1.73 m²) or mild hepatic impairment (Child-Pugh A). Data in moderate to severe hepatic impairment are limited 6.